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ABSTRACT 
Continuous Pharmaceutical Manufacturing (CPM) has a strong potential to catalyse pharmaceutical 
innovation. This paper analyses Continuous Oscillatory Baffled Crystalliser (COBC) optimal design 
and performance for paracetamol crystallisation, via systematic modelling and nonlinear optimization 
(NLP). Clear trends emerge, with rate of antisolvent use having a marked impact of COBC volumes; 
crystal seed mass loading also has a strong effect. For the base case studied (inlet temperature of 
50 °C, seed crystal size of 40 microns) the optimal solution was for 2% seed mass loading (with 
respect to solute mass) and with 80% water antisolvent use (by mass with respect to process solvent 
acetone); the crystalliser size was 4.25 L with a total cost of 101,370 GBP, achieving a product yield 
of 50% with a product crystal size of 83.6 microns. Clear tradeoffs among mass efficiency, volume, 




Pharmaceutical production has long relied solely on batch processing, and while it has many benefits 
including equipment flexibility and the know-how of a mature technology, in an environment of 
growing R&D expenditure (Fig. 1) and a greater awareness of and a drive to be more sustainable, 
research interest has turned towards Continuous Pharmaceutical Manufacturing (CPM); continuous 
production can achieve higher yields purities, better heat and mass transfer, decreased processing 
times, and better efficiency and reliability. The need for cost-effective R&D methodologies brings 
process modelling and simulation to the forefront of initial stages of process option evaluation. 
Furthermore, they are also of great utility in evaluating alternative design parameters for existing or 
newly developed processes (Benyahia et al., 2012). Continuous crystallisation has received significant 
research attention toward developing separation technologies for CPM, with both stirred tanks and 
tubular crystallisers studied (Ferguson et al., 2014; McGlone et al., 2015; Diab and Gerogiorgis, 
2017). Achieving high product quality is also extremely important: accordingly, high-fidelity dynamic 
population balance models and algorithms have been employed to ensure precise control of the output 
Particle Size Distributions (PSD) via cooling and seeding (Shi et al., 2006; Kwon et al., 2014a-c). 
In recent years the continuous synthesis of a range of APIs has been demonstrated, from common 
over-the-counter medications to key anti-cancer drugs (Bogdan et al., 2009; Hopkin et al., 2010). 
While there have been some significant advances with regards to complete ingredient-to-product 
demonstrations of CPM, many aspects of continuous product separation remain to be fully 
investigated (Heider et al., 2014; Baxendale et al., 2015). 
The simulation and cost estimation of process models are invaluable methodologies for evaluating 
the benefits of continuous processing for the production of pharmaceuticals (Gerogiorgis and Barton, 
2009; Rogers et al., 2014; Rogers and Ierapetritou, 2015; Jolliffe and Gerogiorgis, 2015-2017). The 
field of mathematical programming, commonly also called optimisation, has also been utilized to 
great effect, including for many aspects of pharmaceuticals and CPM (Biegler and Grossmann, 2004; 
Gernaey et al., 2012; Escotet-Espinoza et al., 2016).  
Typical examples include the use of the Levenberg-Marquadt algorithm to significantly reduce the 
number of initial approximations required for global optimisation of Lorcaserin synthesis (Grom et al. 
2016). Another example is the optimisation of a small-scale design for continuous ibuprofen synthesis 
(Patel et al., 2011), where in the latter example the objective was the minimisation of the difference 
between heat removed from and heat generated by the microreactor assembly; constraints and bounds 
included residence times, temperature, and concentrations. 
Downstream processes, especially final product formulation, have also attracted significant 
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Figure 1. Economic and market pressures faced by the pharmaceutical industry. A: typical R&D and marketing costs for a 























































research interest in terms of optimisation (Boukouvala and Ierapetritou, 2013; Sen et al., 2013; 
Abejón et al., 2014; Sato et al., 2015). Key research areas include the use of surrogate-based 
optimisation to reduce the computational cost of complex solid-based flowsheet models (Boukouvala 
and Ierapetritou, 2013), the use of reduced-order models combined with population balance models in 
the explicit optimisation of downstream flowsheets using multiple objective functions for each unit 
operation (Sen et al., 2013), and the optimisation of novel technologies such as complex nanofiltration 
cascades (Abejón et al., 2014). 
Life-cycle assessment optimisation is also an interesting aspect of optimisation applied to CPM. Ott 
and co-workers (2014, 2016) have elucidated how multiple rufinamide synthesis routes can be 
comparatively evaluated by the systematic consideration of technical and sustainability performance 
criteria such as Process Mass Intensity (PMI), the Environmental Factor (E-factor) and Life Cycle 
Impact Assessments (LCIA), with the latter being reduced by 45 % as a result. 
In previous work, we have used modelling and simulation to economically evaluate two CPM 
processes, and we have also used nonlinear optimisation of these process models to determine optimal 
design and operating parameters for key product separation operations (Jolliffe and Gerogiorgis, 
2017a, 2017b). In the present work, we systematically incorporate models for continuous 
crystallisation, published crystallisation kinetic data, and economic analysis into a nonlinear 
optimisation model to determine optimal crystallisation operation and design for the recovery of an 
analgaesic Active Pharmaceutical Ingredient (API), paracetamol. This key API has been widely used 
as a model API for CPM studies, with published data on crystallisation kinetics available (Brown et 
al., 2015; Cruz et al., 2016). The impact of temperature, crystalliser size and configuration, antisolvent 
type and quantity, and flowrate are considered. The optimisation cases are formulated into a nonlinear 
optimisation model to determine optimal Continuous Oscillatory Baffled Crystalliser design variables 
and process conditions. Technical metrics (such as product recovery), Green Chemistry metrics (E-
factor), and economic metrics (Capital Expenditure, CapEx) are used for process evaluation. 
1.1 Continuous Oscillatory Baffled Crystallisers (COBC) 
Continuous Oscillatory Baffled Crystallisers (COBC) are a development resulting from Oscillatory 
Baffled Reactors: they comprise a series of baffles in long (i.e. high length-to-diameter ratio) tubes, 
and in appearance are similar to Plug Flow crystallisers with baffles. COBC units tend to offer 
improved performance over the latter, as well as over batch crystallisers. They offer improved scaling, 
heat and mass transfer and decreased processing times (Lawton et al., 2009). COBC units operate by 
inducing an oscillatory flow in the fluid contents, and there is also a net flow through the unit (as this 
is a continuous process) which is independent of the oscillatory flow. The use of a reciprocating pump 
is a common way to generate the oscillatory flow, and as the fluid moves back and forth across the 
baffles eddies are generated which enhance mixing and therefore performance. Baffles design 
primarily varies in terms of the orifice-to-internal diameter ratio, the gap between the baffles and the 






Figure 2. Typical examples of oscillatory baffled crystalliser design (Hodges, 2015; McGlone et al., 2015). 
Net fluid/slurry flow
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2 PROCESS MODEL AND NONLINEAR OPTIMISATION 
The objective function to be minimized is a Capital Expenditure (CapEx) function (Equation 1), from 
a capacity-power law using crystalliser volume. The coefficient a and exponent n were generated by 
fitting publicly available data for cost and capacity of commercial COBC units. Crystalliser volume is 
computed in a relatively straightforward manner (Equation 2), from total volumetric throughput and 
the residence time required to achieve the desired objectives (such as yield). The population balance 
(Equation 3) and mass balance (Equation 4) are solved via a moment transformation (Equation 5) 
(Brown et al., 2014). Key variables in (Equation 5) include characteristic crystal length L (m), growth 
rate G (m s–1).  
There are two main forms which are encountered, forms I and II (Fig. 3). Form I is monoclinic and 
forms more readily, and Form II is orthorhombic and metastable. Indeed, active measures must often 
be taken to promote the formation of Form II. Here in this work, Form I is assumed, as the empirical 
correlations to estimate growth rate are based on experimental work where Form I was present; the 
volume shape factor kv is taken to be 0.866 (Brown and Ni, 2011). Crystal density ρAPI is 1.3 g cm
–3. 
Nucleation is considered to be negligible, so the Bro
j terms in Equation (5) are ignored. Growth rate 
G is computed via an empirical correlation (Equation 6) (Brown and Ni, 2011), where ΔCAPI is the 
degree of supersaturation (Equation 7), Q̇AS is the rate of antisolvent addition in mL min
–1, and Reo the 
oscillatory flow Reynold Number (Equation 9).  
In the oscillatory flow Reynold Number, angular velocity ω = 2πfoscaosc (m s
–1) replaces the 
superficial fluid velocity found in the normal (Net Flow) Reynolds Number (Ren, Equation 9). Here, 
fosc and aosc are the frequency and amplitude of the fluid oscillation, respectively (normally taken to be 
2 Hz and 10 mm in this model). In the literature, values for both Reo and Ren are suggested to achieve 
the best mixing, often above 300 for the former and above 50 for the latter. In this model we have 
imposed similar requirements, although with a higher Reo; values over 4,000 have been used in 
experimental work (Brown and Ni, 2011). There is also ψ, the ratio of Reo and Ren, and again the 
literature suggests a range for best mixing, which has been employed in this study. The ranges listed 
in Equation (9) are not hard constraints, and in some cases operation falls outside by 10%. 
The solubility of paracetamol in different solvent systems has been commonly studied in the 
literature. Here, the use acetone as process solvent is modelled, with either water or toluene as 
antisolvent. Empirical values for paracetamol were taken fitted high order polynomial surrogate 
equations to calculate solubilities (Equation 8). With water use there is a solubility peak, and within a 
certain range adding water will in fact increase API solubility. To avoid this, the rate of antisolvent 
 
Figure 3. Paracetamol molecular structure and typical crystal polymorphs (Brown and Ni, 2011; Sudha and Srinivasan, 
2013). 
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use was limited to a range of 50:50 to 20:80 by weight (process solvent acetone : antisolvent). 
Because using toluene has been found to result in highly impractical residence times and volumes 
(very long/large); the results presented here refer to the use of water as an antisolvent. 
Seed crystal loading can vary from 0.5% to 2.0% by weight (seed w.r.t. solvent and antisolvent). 
The following assumptions are made: a) seed crystals are monodisperse (i.e. of same size) and of 
monoclinic Form I; b) no nucleation, agglomeration or breakage of crystals; c) crystal growth rates 
are size-independent; d) no impurities; e) sufficient heat transfer available to maintain a linear cooling 
profile. In terms of temperature, the inlet temperature can vary between 30 to 70 °C, and cooled to 
5 °C; an inlet temperature of 50 °C has been the default studied, with other values investigated to see 
how optimal points change. Likewise, seed crystal size was 40 microns by default, in order to ensure 
that the correlation used complies with literature (Brown and Ni, 2011); only crystal sizes equal to or 
higher than this threshold have been investigated, to study the variation of optima. Separate 
optimisation cases have been solved for varying inlet temperature and varying seed crystal size. 
The solver employed is a constrained minimization solver using the trust region reflective 
algorithm, with tolerances (stopping criteria) set to 10–6. Gradients were computed by the solver itself, 
and the solution time was reasonably fast at between 30–100 seconds; these values are the time 
required to generate capital expenditure response surfaces, and the time to run a single optimisation 
case was faster at 5–10 seconds. As stated, separate cases were formulated for initial temperatures. 
Separate cases were also performed for seed crystal sizes. A quick global search was performed by 
checking convergence from multiple initial starting points; the runs always converged to the same 
point, and the absence of local minima can be concluded with good confidence. 
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3 RESULTS AND DISCUSSION 
3.1 Dynamic simulation of crystallisation evolution 
Plotting the trajectories of some key variables shows the expected trends (Fig. 5). The yield takes time 
to develop, as the growth rate is initially slow. As time progresses (i.e. the material moves through the 
crystalliser), the supersaturation grows as the API precipitation does not keep pace with the 
decreasing solubility, the latter coming from the temperature decreasing in a linear manner). As the 
supersaturation – the gap between the blue solubility curve and the red concentration curve – 
increases, the growth rate begins to increase, naturally leading to an enhancement of the rate of yield 
increase. Eventually, the concentration lowers to the point where the trend reverses and the 
supersaturation begins to decrease, at which point there is an inflection in the yield trajectory, and the 
yield begins to trend towards a plateau. 
Figure 5. Trajectory of key process variables. The seed crystal size is 40 microns and the outlet temperature is 5 °C, and the 
inlet temperature is 50 °C. 
Table 1. Optima variation for differing inlet temperatures (left) and seed crystal size (right).
          























70 37.032 0.941 91 118.0 80 161.060 8.499 822 167. 2 
60 60.337 1.954 189 99.2 70 147.280 7.435 719 146.3 
50 101.370 4.250 411 83.6 60 132.970 6.380 617 125.4 
40 170.600 9.265 896 71.5 50 117.700 5.315 514 104.5 






























     
 
Figure 6. Trajectories of key process variables. In all cases the seed crystal size is 40 microns and the outlet temperature is 5 
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Ls = 40 μm 
VCOBC (50 °C Tin)
VCOBC (70 °C Tin)
Lp          (50 °C Tin)







































The estimation of the growth rate is a key aspect in this paper. The correlation used (Equation 6) 
has developed by Brown and Ni (Brown and Ni, 2011). Based on data acquired by visual (camera) 
analysis, it is applicable for crystal sizes of 43 microns and above: this was the smallest crystal size 
captured therein (1 pixel: 43 microns). In batch crystallisation, using seed crystals is common, 
because they only need be added once per batch. However, in this work, as nucleation has been 
considered negligible due to the conditions and the data available (e.g. Brown and Ni, 2011), the 
continuous addition of seed crystals has been deemed required. Because crystallisation recovers more 
API than is injected via seed crystals, continuous seed crystal addition can be avoided if nucleation 
advances at acceptably high rates; thus, investigating paracetamol nucleation kinetics will be of great 
benefit, to develop a crystal growth rate correlation (similar to Equation 6). Under nucleation, a key 
difference expected is a non-uniform crystal size, as nucleation would not occur only at the start, but 
throughout the crystalliser, subject to the operating conditions. The time required to achieve the 
desired yield, and hence the required crystalliser volume and cost, would certainly change as well. 
 
The trajectories shown in Fig. 5 are for the case of an inlet temperature of 50 °C and seed crystal size 
of 40 microns, and a target yield of 50%; it corresponds to the response surfaces in Fig. 4, and the 
optimum is for seed mass loading of 2% and an antisolvent fraction of 80% (weight). Achieving 
higher yields under the same conditions becomes increasingly difficult, as illustrated in Fig. 6. The 
thermodynamic constraints imposed on the system (via the solubility behaviour) from using an inlet 
temperature of 50 °C means that compared to achieving 50% yield (Fig. 6, top trajectory) the 
supersaturation is very small by the time 80% yield is achieved (Fig. 6, middle trajectory). In these 
conditions growth rate is very low, and it takes a long time to reach the required performance (i.e. 
requiring a larger crystalliser as the regime is plug flow). One possible way to achieve higher yields in 
less time and in smaller crystallisers would be of course to operate at a higher inlet temperature (Fig. 
6, bottom trajectory). With other conditions constant, a higher initial temperature allows a greater 
supersaturation to be maintained, achieving high yields in a reasonable time and crystalliser size. 
































Seed mass rate (SMR), gseed/gsolute Mass percent of antisolvent  (toluene) Mass percent of antisolvent  (toluene) 





Figure 8. Variation of COBC volume and product crystal size with inlet temperature (left; constant seed crystal size) and 


















































Inlet temperature Tin, (°C)
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Seed crystal size Ls, (μm)
mAS = 80 %
SMR =   2 %
Tin = 50 °C 
VCOBC (50% yield)
VCOBC (70% yield)
Lp          (50% yield)







3.2 Crystalliser volume and product crystal size 
The response surface for product crystal size is given in Fig. 7. Lower antisolvent amount results in 
larger product crystals; again, this is an effect of seed count. With lower antisolvent amount, the mass 
of seed crystals added in absolute terms is less. Therefore, the seed count will lower, meaning crystals 
must grow more to achieve the same yield. The reason lower seed mass loading increases product size 
is for the same reason.  
Table 1 presents how volume, residence time and product crystal size vary with seed crystal size, 
for the same inlet temperature of 50 °C; optima variation is less pronounced as with different inlet 
temperatures. Regarding the increasing product crystal size with inlet temperature (and lowering with 
lower inlet temperature), this makes sense, as we assume the same initial supersaturation ratio (S = 
1.5, Equation 7) in all cases: the higher the inlet temperature the higher the inlet solubility, thus higher 
supersaturation, thus greater API content, thus greater API precipitation for the same yield, thus larger 
product crystal sizes (as seed count is the same).Of course, for a given seed mass loading, larger seed 
crystal sizes mean lower seed counts. These results are presented graphically in Fig. 8.  
Also in Fig. 8 are presented values for when the target yield is 70 % (circles) instead of 50 %. As 
can be expected, a greater target yield leads to larger required crystalliser volumes for a given inlet 
temperature or seed crystal size. Also evident is the larger product crystal sizes from reaching a higher 
yield, which would be expected.  
The change in required COBC volumes with the oscillation frequency and amplitude (Fig. 9) 
produce a clear trend of lower volumes; this is to be expected, as higher ω increases Reo, which 
increases growth rates. The variation of volumes and product crystal sizes for different required target 
yields (other results presented in this work are for yields of 50 %) is also illustrated in Fig. 6; again, 
the inlet temperature is 50 °C and the seed crystal size is 40 microns. The product crystal size 
increases fairly linearly. In contrast, the required crystal volumes exponentially increase, and indeed 
 
Figure 9. Variation of COBC volume with angular velocity of the oscillatory fluid motion (left) and variation of COBC 
volume and product crystal size with different crystallisation yield targets (right). In both cases there is constant inlet 



















































Angular velocity ω = 2πfxo, (m/s)
mAS = 80 %
SMR   =   2 %
Tin = 50 °C
Ls = 40  μm
Yield  = 50 %
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achieving 90% yield is impractical (under the given conditions; as previously discussed, differing 
operating temperatures for example can make higher yields achievable). 
3.3 Crystalliser cost 
Given a desired yield of 50 %, the total cost response surface for an inlet temperature of 50 °C and a 
seed crystal size of 40 microns is given in Fig. 10. The optimal solution (cost = 101,370 GBP) is 
pushed to bounds. It is evident that the rate of antisolvent use affects the total cost more significantly 
than the seed mass loading. Greater rates of antisolvent use result in lower costs via lower required 
residence times, due to faster growth rates. The tabulated values (Table 1) illustrate how the optimum 
changes with varying inlet temperatures, with a constant seed crystal size of 40 microns. Increasing 
the inlet temperature can drastically lower the cost via small required volumes and residence times. 
Crystalliser cost here is defined as the Capital Expenditure, calculated from a power-law 
relationship with crystalliser volume (Equation 1). More detailed design and cost estimations could 
include a more explicit relation between unit operation design and cost, as well as the inclusion of 
additional sources of cost contributing to the Capital Expenditure (such as installation costs) or the 
inclusion of Operating Expenditure (which could indeed be expected to vary with size, capacity and 
operation). However, as the process being evaluated here is a single crystallisation operation on its 
own, with no upstream or downstream operations, inclusion of additional cost detail as described 
above is complicated. In essence, what is performed here is an evaluation of how a variables such as 
inlet temperature, target yield, and seed crystal size affect the required crystalliser volumes, with the 
cost calculated as another way to visualise the response of the crystalliser volumes. 
3.4 Material efficiency (E-factor) 
The E-factor, first used by Sheldon (2012), is a versatile and useful Green Chemistry metric. The 
simplest definition the E-factor is the quantity of waste generated per unit of product, in mass terms. 

































Seed mass rate (SMR), gseed/gsolute Mass percent of antisolvent  (toluene) Mass percent of antisolvent  (toluene) 
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Values as high as 200 for the E-factor are not uncommon for pharmaceutical process, which are 
invariably batch operations; this in contrast to those highly efficient industries which very heavily rely 
on continuous production techniques, such as the oil and gas sector, which have representative E-
factors in the order of 0.1, indicating significantly less amounts of relative waste amounts (Ritter, 
2013). In this work, the E-factor is computed where the product is (pure) recovered API, while the 
waste consists of waste solvent and antisolvent and unrecovered API. Evaluating E-factors (Fig. 11), 
we can see that for a given yield they worsen with increasing antisolvent quantity; E-factor is 
invariant with seed mass loading. However, with worsening E-factor, costs improve, highlighting the 
frequently conflicting requirements in process design and evaluation. 
4 CONCLUSIONS 
The solved optimisation cases illustrate the benefits and drawbacks of different combinations of 
solvent and antisolvent, in both technical and sustainability terms, and the varying impacts of inlet 
temperature, seed mass loading, seed crystal size, mechanical operation of the crystalliser, and rate of 
antisolvent use. For a desired yield of 50%, the latter has the most significant effect on crystalliser 
cost (Capital Expenditure), while seed mass loading also has a strong effect. Higher required yields 
require exponentially larger and costlier crystallisers. Paracetamol nucleation and growth kinetics can 
be readily incorporated in the model presented. The tradeoff between material efficiency (or E-factor), 
COBC volume and cost underscores the competing objectives frequently arising in process design. 
 
ACKNOWLEDGEMENTS 
The authors gratefully acknowledge the financial support of the Engineering and Physical Sciences 
Research Council (EPSRC) via a Doctoral Training Partnership (DTP) studentship awarded to Mr 
H.G. Jolliffe. Moreover, Dr D.I. Gerogiorgis acknowledges a Royal Academy of Engineering 
(RAEng) Industrial Fellowship. Tabulated and cited literature data suffice for reproduction of all 
original process simulation and optimisation results, and no other supporting data are required to 
ensure reproducibility. 
 



























Mass percent of antisolvent mAS
Yield = 50 % 
mAS     = 80 %
mseed =   2 %
Tin      = 50 °C




a Cost coefficient for crystalliser cost estimation via Equation (1), GBP 
aosc Amplitude of oscillation, m 
ASR Mass fraction of antisolvent (balance is process solvent) 
B Nucleation rate, s-1 
CAPI API solute concentration, g cm
–3 
ΔCAPI Degree of supersaturation, g cm
–3 
CAPI
sat Saturation API solute concentration, g cm–3 
d Internal diameter of the Continuous Oscillatory Baffled Crystalliser, m 
fosc Frequency of oscillation, Hz 
G Growth rate, m s–1 
kv  Volume shape factor 
L Size (length) of crystals, m 
Lp Size (length) of product crystals, m 
Ls Size (length) of seed crystals, m 
m Exponent in Equation (1) 
mAS Mass percent of antisolvent (balance is process solvent) 
n Number of crystals 
Q̇AS rate of antisolvent addition, mL min
–1 
Q̇Tot Volumetric flowrate, Ls
-1 
Ren Net flow Reynolds Number 
Reo oscillatory flow Reynold Number 
ro Radius of nucleating crystal, m 
S Supersaturation ratio 
SMR Seed mass rate 
T Temperature, K 
Tin Inlet temperature, K 
t Time, s 
unet Bulk fluid superficial velocity, m s
-1 
VCOBC Crystalliser volume, L 
μj jth moment 
μmix Bulk fluid viscosity, Pa s 
ρAPI Crystal density, g cm
–3 
ρmix Fluid bulk density, kg m
–3 
τreq Required residence time, s 
ψ Ratio of Reo and Ren 
ω Oscillatory flow angular velocity, m s–1 
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